Volume 30, Number 7—July 2024
Dispatch
Risk for Donor-Derived Syphilis after Kidney Transplantation, China, 2007–2022
Saifu Yin1, Lijuan Wu1, Congke Liu1, Zihao Jia1, Jiapei Wu, Fan Zhang, Xianding Wang, Turun Song
, and Tao Lin
, and Tao Lin
Table
Baseline characteristics of 102 kidney transplantation pairs, western China, 2007–2022*
| Characteristics | No. (%) patients |
p value | |||
|---|---|---|---|---|---|
| Overall, n = 102 | CLIA+/TPPA–/TRUST–, n = 13 | CLIA+/TPPA+/TRUST–, n = 45 | CLIA+/TPPA+/TRUST+, n = 44 | ||
| Donor | |||||
| Type | 0.848† | ||||
| Deceased | 52 (51.0) | 7 (53.8) | 24 (53.3) | 21 (47.7) | |
| Living | 50 (49.0) | 6 (46.2) | 21 (46.7) | 23 (52.3) | |
| Living donor-recipient relationship | 0.799‡ | ||||
| Spouses | 3 (6.0) | 0 | 1 (4.8) | 2 (8.7) | |
| Parent-Child | 35 (70.0) | 4 (66.7) | 14 (66.7) | 17 (73.9) | |
| Siblings | 12 (24.0) | 2 (33.3) | 6 (28.6) | 4 (17.4) | |
| Sex | 0.390‡ | ||||
| M | 53 (52.0) | 9 (69.2) | 23 (51.1) | 21 (47.7) | |
| F | 49 (48.0) | 4 (30.8) | 22 (48.9) | 23 (52.3) | |
| Mean age, y (± SD) | 48.7 (8.9) | 54.3 (6.2) | 47.7 (6.7) | 48.0 (10.8) | 0.047§ |
| Syphilis treatment of the living donor before donation | <0.001‡ | ||||
| Penicillin | 16 (32.0) | 0 | 13 (61.9) | 3 (13.0) | |
| None |
34 (68.0) |
6 (100) |
8 (38.1) |
20 (87.0) |
|
| Recipient | |||||
| Sex | 0.001‡ | ||||
| M | 73 (71.6) | 4 (30.8) | 37 (82.2) | 32 (72.7) | |
| F | 29 (28.4) | 9 (69.2) | 8 (17.8) | 12 (27.3) | |
| Mean age, y (± SD) | 33.5 (9.8) | 37.7 (9.6) | 32.4 (10.0) | 33.5 (9.4) | 0.224§ |
| Hemodialysis | 0.648‡ | ||||
| No | 17 (16.7) | 1 (7.7) | 8 (17.8) | 8 (18.2) | |
| Yes | 85 (83.3) | 12 (92.3) | 37 (82.2) | 36 (81.8) | |
| Peritoneal dialysis | 0.892‡ | ||||
| No | 92 (90.2) | 12 (92.3) | 41 (91.1) | 39 (88.6) | |
| Yes | 10 (9.8) | 1 (7.7) | 4 (8.9) | 5 (11.4) | |
| Mean duration dialysis, mo, (± SD) | 12.8 (16.0) | 19.8 (26.8) | 11.8 (14.6) | 11.7 (13.0) | 0.243¶ |
| Induction therapy | 0.534‡ | ||||
| Anti-thymocyte globulin | 26 (25.5) | 3 (23.1) | 12 (26.7) | 11 (25.0) | |
| Basiliximab | 66 (64.7) | 7 (53.8) | 30 (66.7) | 29 (65.9) | |
| None | 10 (9.8) | 3 (23.1) | 3 (6.7) | 4 (9.1) | |
| Maintenance immunosuppressive therapy | 0.022‡ | ||||
| Cyclosporine | 3 (2.9) | 2 (15.4) | 0 (0.0) | 1 (2.3) | |
| Tacrolimus | 99 (97.1) | 11 (84.6) | 45 (100.0) | 43 (97.7) | |
| Antimicrobial use | 0.016‡ | ||||
| Aztreonam | 3 (2.9) | 0 | 2 (4.4) | 1 (2.3) | |
| Cefmetazole | 47 (46.1) | 7 (53.8) | 23 (51.1) | 17 (38.6) | |
| Cefoperazone | 4 (3.9) | 0 | 4 (8.9) | 0 | |
| Ceftriaxone | 32 (31.4) | 2 (15.4) | 9 (20.0) | 21 (47.7) | |
| Cefoxitin | 2 (2.0) | 0 | 2 (4.4) | 0 | |
| Ceftizoxime | 10 (9.8) | 4 (30.8) | 2 (4.4) | 4 (9.1) | |
| Imipenem–cilastatin | 4 (3.9) | 0 | 3 (6.7) | 1 (2.3) | |
*Persons were from Sichuan, Chongqing, Tibet, Qinghai, Gansu, Guizhou, Yunnan, Guangxi, Shanxi, and Xinjiang Province, China. CLIA, chemiluminescence immunoassay; mNGS, metagenomic next-generation sequencing; TPPA, Treponema pallidum particle agglutination; TRUST, toluidine red unheated serum test. †By χ2 test. ‡By Fisher exact test. §By Student t-test. ¶By Wilcoxon–Mann–Whitney U-test.
1These authors contributed equally to this article.
Page created: May 23, 2024
Page updated: June 22, 2024
Page reviewed: June 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.